Skip to main content

The AHRQ National Quality Measures Clearinghouse (NQMC, qualitymeasures.ahrq.gov) Web site will not be available after July 16, 2018 because federal funding
through AHRQ will no longer be available to support the NQMC as of that date. For additional information, read our full announcement.
  • Measure Summary
  • NQMC:010691
  • Dec 2015

Hematology: percentage of patients with multiple myeloma ever treated with a bisphosphonate.

American Society of Hematology (ASH). Multiple myeloma (MM) measure specifications. Washington (DC): American Society of Hematology (ASH); 2015 Dec. 2 p.

This is the current release of the measure.

This measure updates a previous version: American Society of Hematology, Physician Consortium for Performance Improvement®. Hematology physician performance measurement set. Washington (DC): American Society of Hematology (ASH); 2014 Nov. 17 p.

The measure developer reaffirmed the currency of this measure in February 2017.

Primary Measure Domain

Clinical Quality Measures: Process

Secondary Measure Domain

Does not apply to this measure

Description

This measure is used to assess the percentage of patients with multiple myeloma ever treated with a bisphosphonate.

Rationale

Bony manifestations of myeloma, in the form of diffuse osteopenia and/or osteolytic lesions, develop in 85% of patients. Related complications are the major cause of limitations in quality of life and performance status in patients with multiple myeloma (MM). A large, double-blind, randomized trial has shown that monthly use of intravenous pamidronate (a bisphosphonate) can decrease pain and bone-related complications, improve performance status, and, importantly, preserve quality of life in patients with Durie-Salmon stage III MM and at least one lytic lesion.

The National Comprehensive Cancer Network (NCCN) Guidelines for Multiple Myeloma recommend bisphosphonates for all patients receiving myeloma therapy for symptomatic disease regardless of documented bone disease (NCCN, 2015).

In patients with smoldering or stage I MM, according to the NCCN Panel, bisphosphonates may be considered but preferably in a clinical trial (NCCN, 2015).

Evidence for Rationale

American Society of Hematology (ASH). Multiple myeloma (MM) measure specifications. Washington (DC): American Society of Hematology (ASH); 2015 Dec. 2 p.

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: multiple myeloma. V2.2016 [slide set]. Fort Washington (PA): National Comprehensive Cancer Network (NCCN); 2015.

Primary Health Components

Multiple myeloma; bisphosphonate

Denominator Description

The number of patients in your selection with multiple myeloma International Classification of Diseases, Tenth Revision (ICD-10) code C90.00 (not in remission) or C90.02 (in relapse) (see the related "Denominator Inclusions/Exclusions" field)

Numerator Description

The number of patients in your selection with multiple myeloma International Classification of Diseases, Tenth Revision (ICD-10) code C90.00 (not in remission) or C90.02 (in relapse)

AND

Treated with a bisphosphonate

See the related "Numerator Inclusions/Exclusions" field.

Type of Evidence Supporting the Criterion of Quality for the Measure

  • A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence

Additional Information Supporting Need for the Measure

Unspecified

Extent of Measure Testing

The American Medical Association (AMA)-convened Physician Consortium for Performance Improvement (PCPI) in collaboration with the American Society of Hematology (ASH) conducted a measure testing project from May to September of 2010 to ensure that all four hematology measures were feasible to implement and reliable. Two testing projects were conducted utilizing patient records in the electronic health record (EHR) environment and claims data. The two sites were located in different United States (U.S.) states and were selected based on their ability to meet the measure testing site criteria. Site 1 was a small-scale hematology group practice and Site 2 was a large-scale multi-specialty group clinic; both sites were in an urban setting.

Reliability Testing

The purpose of reliability testing was to evaluate whether the measure definitions and specifications, as prepared by the PCPI, yield stable, consistent measures. Measures were tested using information stored in the EHR environment and claims data from both sites. Inter-rater reliability was performed in the EHR environment. Parallel forms reliability was performed reviewing Physician Quality Reporting System (PQRS) claims information compared to a manual review of the patient chart.

Reliability Testing Results

Overall the measures were found to be reliable. Inter-rate reliability testing was conducted and Kappa statistics were calculated for the measures, which demonstrated almost perfect agreement.

One of the two measure testing sites participated in the PQRS program and submitted claims comparison on two measures. PQRS claims were reviewed and information was verified in the record review for a significant portion of these charts.

Evidence for Extent of Measure Testing

American Society of Hematology, Physician Consortium for Performance Improvement®. Hematology physician performance measurement set. Washington (DC): American Society of Hematology (ASH); 2014 Nov. 17 p. [6 references]

State of Use

Current routine use

Current Use

Internal quality improvement

Pay-for-reporting

Public reporting

Measurement Setting

Ambulatory/Office-based Care

Professionals Involved in Delivery of Health Services

Physicians

Least Aggregated Level of Services Delivery Addressed

Individual Clinicians or Public Health Professionals

Statement of Acceptable Minimum Sample Size

Does not apply to this measure

Target Population Age

Unspecified

Target Population Gender

Either male or female

National Quality Strategy Aim

Better Care

National Quality Strategy Priority

Prevention and Treatment of Leading Causes of Mortality

IOM Care Need

Living with Illness

IOM Domain

Effectiveness

Case Finding Period

Unspecified

Denominator Sampling Frame

Patients associated with provider

Denominator (Index) Event or Characteristic

Clinical Condition

Denominator Time Window

Does not apply to this measure

Denominator Inclusions/Exclusions

Inclusions
The number of patients in your selection with multiple myeloma International Classification of Diseases, Tenth Revision (ICD-10) code C90.00 (not in remission) or C90.02 (in relapse)

Exclusions

  • Patients without bony lesions or osteopenia
  • Patients with renal insufficiency and not on dialysis
  • Patients with dental disease

Exclusions/Exceptions

Medical factors addressed

Numerator Inclusions/Exclusions

Inclusions
The number of patients in your selection with multiple myeloma International Classification of Diseases, Tenth Revision (ICD-10) code C90.00 (not in remission) or C90.02 (in relapse)

AND

Treated with a bisphosphonate

Note: Refer to the original measure documentation for a list of Healthcare Common Procedure Coding System (HCPCS) codes for included bisphosphonates.

Exclusions
Unspecified

Numerator Search Strategy

Fixed time period or point in time

Data Source

Administrative clinical data

Electronic health/medical record

Paper medical record

Type of Health State

Does not apply to this measure

Instruments Used and/or Associated with the Measure

Unspecified

Measure Specifies Disaggregation

Does not apply to this measure

Scoring

Rate/Proportion

Interpretation of Score

Desired value is a higher score

Allowance for Patient or Population Factors

Unspecified

Standard of Comparison

Internal time comparison

Original Title

Measure 6: patient with multiple myeloma, ever treated with a bisphosphonate.

Measure Collection Name

Hematology Measure Set

Submitter

American Society of Hematology - Medical Specialty Society

Developer

American Society of Hematology - Medical Specialty Society

Funding Source(s)

The American Society of Hematology

Composition of the Group that Developed the Measure

Hematology Work Group: Steven L. Allen, MD (Co-chair, hematology/oncology); William E. Golden, MD (Co-chair, internal medicine [IM]); Kenneth Adler, MD (hematology/IM); Daniel Halevy, MD (nephrology); Stuart Henochowicz, MD, MBA (IM); Timothy Miley, MD (hematopathology); David Morris, MD (radiation oncology); John M. Rainey, MD (medical oncology); Samuel M. Silver, MD, PhD (hematology/oncology); Lawrence Solberg, Jr., MD, PhD (hematology/IM)

American Society of Hematology: Mila Becker, Esq.; Pamela Ferraro, MS; Sue Frechette, BSN, MBA (Consultant)

American Medical Association: Karen S. Kmetik, PhD; Samantha Tierney, MPH

American Society of Clinical Oncology: Kristen McNiff, MPH

American Society for Therapeutic Radiology and Oncology: Emily Wilson

Leukemia and Lymphoma Society: Hildy Dillon, MPH; Mary Grace Pagaduan, MPH

Centers for Medicare & Medicaid Services: Sue Nedza, MD, MBA, FACEP; Sylvia Publ, MBA, RHIA

Physician Consortium for Performance Improvement (PCPI) Consultants: Rebecca Kresowik; Timothy F. Kresowik, MD

Financial Disclosures/Other Potential Conflicts of Interest

Conflicts, if any, are disclosed in accordance with the Physician Consortium for Performance Improvement® conflict of interest policy.

Measure Initiative(s)

Physician Quality Reporting System

Adaptation

This measure was not adapted from another source.

Date of Most Current Version in NQMC

2015 Dec

Measure Maintenance

American Society of Hematology (ASH) reviews/updates measures annually

Date of Next Anticipated Revision

Unspecified

Measure Status

This is the current release of the measure.

This measure updates a previous version: American Society of Hematology, Physician Consortium for Performance Improvement®. Hematology physician performance measurement set. Washington (DC): American Society of Hematology (ASH); 2014 Nov. 17 p.

The measure developer reaffirmed the currency of this measure in February 2017.

Source(s)

American Society of Hematology (ASH). Multiple myeloma (MM) measure specifications. Washington (DC): American Society of Hematology (ASH); 2015 Dec. 2 p.

Measure Availability

Source not available electronically.

For more information, contact Robert M. Plovnick, MD, MS, Director of Quality Improvement Programs at the American Society of Hematology, 2021 L Street NW, Suite 900 Washington, DC 20036; Phone: 202-776-0544; Fax: 202-776-0545; Web site: www.hematology.org External Web Site Policy.

NQMC Status

This NQMC summary was completed by ECRI Institute on September 13, 2007. The information was verified by the measure developer on October 26, 2007.

This NQMC summary was edited by ECRI Institute on September 1, 2009.

This NQMC summary was retrofitted into the new template on June 6, 2011.

This NQMC summary was edited again by ECRI Institute on April 27, 2012.

Stewardship for this measure was transferred from the PCPI to the ASH. ASH informed NQMC that this measure was updated. This NQMC summary was updated by ECRI Institute on July 28, 2015. The information was verified by the measure developer on August 27, 2015.

This NQMC summary was updated again by ECRI Institute on April 18, 2016. The information was verified by the measure developer on May 24, 2016.

The information was reaffirmed by the measure developer on February 14, 2017.

Copyright Statement

This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.

For more information, contact Robert M. Plovnick, MD, MS, Director of Quality Improvement Programs at the American Society of Hematology, 2021 L Street NW, Suite 900 Washington, DC 20036; Phone: 202-776-0544; Fax: 202-776-0545; Web site: www.hematology.org External Web Site Policy.

NQMC Disclaimer

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.